AIDDS

In the past, the purpose of treatment was to cure disease, but now people are more interested in preventing disease than curing it. This means a paradigm shift. As reflected in this, Korean medical examination market has exceeded 4 billion USD as of 2020.

​

Korean cancer incidence rate (per 100,000 population) is 275.4, which is lower than the OECD average (301.1), but has been steadily increasing since 2016. As of 2020, the number of new cancer patients per year exceeded 250,000.

Although the incidence of gastric cancer, colorectal cancer, liver cancer, and cervical cancer has been declining for the past 10 years, breast cancer has steadily increased over the past 20 years, and as of 2020, it has exceeded 25,000.

​

Neurodigm has completed AIDDS, a platform for predicting and diagnosing diseases to prevent diseases in the line with thie new paradigm.

​

AIDDS can omit the difficult chemotherapy process by judging the suitability of chemotherapy to ensure the quality of life of cancer patients. For diabetic patients, it is necessary to predict hypoglycemia in advance so that they do not fall into a dangerous situation.

It helps you to manage your health in advance through prevention, not cure. In addition, accurate biomarkers are extracted and provided for the development of new drugs for effective disease treatment.